

-continued

```

TTAAGTAACCCAAACCAAAGTGTGAAGATTAAGAAAAAGCGGCCGAG
AGCTC
VP40 (SEQ ID NO:1048):
GGTACCTCGAGGATGAAGATTAAGAAAAACCTACCTCGGCTGAGAGAGTG
TTTTTCATTAACCTCATCTGTAAACGTTGAGCAAATTGTTAAAAT
ATGAGGGGGTTATTCGCTACTGCTCCTCTGAAATATGAGGCCAT
ATACCCGTCAAGGTCAAATTCAACAATTGCTAGAGGTGGCACAGCAATA
CAGGCTCCTGACACCGGAGTCAGTCATGGGACACTCCATCGAATCCA
CTCAGGCCAATTGCCGATGACCATCGACCATGCCAGCCACACCCAGG
CAGTGTGTCATCAGCATTCTGAAGCTATGGTGAATGTCATATCGG
GCCCAAAGTGTAAATGAAGCAAATCCATTGGTGCCTCTAGGTGTC
GCTGATCAAAGACCTACAGCTTGACTCAACTACGGCGCAATTATGCT
CGCATCTTACGATCACCCATTGCGCAAGGCAACCAACCCCTCGTTA
GAGTGAATCGACTGGTCCTGGAATCCGGATCATCCCTCAGGCTCCTG
CGAATTGGAAACCAGGCTTCCTCCAGGAGTCGTTCTCCGCCAGTCCA
ACTACCCAGTATTCACCTTGATTGACAGCACTCAAACGTACACCC
AACCACTGCCTGCTGCAACATGGACCGATGACACTCCAACAGGATCAAAT

```

-continued

```

GGAGCGTTGCGTCAGGAATTTCATTTCATCCAAAACCTCGCCCCATTCT
TTTACCCAAACAAAGTGGAAAGAAGGGGACAGTGCGCATCTAACATCTC
CGGAGAAAATCCAAGCAATAATGACTTCAGGACTTAAGATCGT
CCAATTGATCCAGCCAAGAGTATCATTGGATCGAGGTGCCAGAAACTCT
GGTCCACAAGCTGACCGTAAGAAGGTGACTCTAAAATGGACAACCAA
TCATCCCTGTTTGTGAAAGTACATTGGTTGGACCCGGTGGCTCCA
GGAGACCTCACCATGGTAAATCACACAGGATTGTGACACGTGTCATTCTCC
TGCAAGTCTCCAGCTGTGATTGAGAAGTAATTGCAATAATTGACTCAGA
TCCAGTTTATAGAATCTCTCAGGGATAGCAACTCAATCGACTTTAGG
ACCGTCATTAGAGGAGACACTTTAATTGAAAATGACTAATCGGTC
AAGGACCATTTGTCATTCCTCTCCTAAATGTAGAACTTAACAAAGACT
CATATAACTTGTTTAAAGGATTGATTGATGAAAGAACATGCATAAG
CGATCCATCTGCCCTACTATAATCAATACGGTGATTCAAATGTTAAT
CTTCTCATGGCACATACTTTGCCCTTATCCTCAAATTGCGCATGC
TTACATCTGAGGATAGCCAGTGTGACTGGATTGGAAATGTGGAGAAAAA
ATCGGGACCCATTCTAGGTTGTTCAACATCCAAGTACAGACATTGCCCT
TCTAATTAGAAAAAGCGGCCGCAGAGCTC

```

[0226] Other embodiments are in the claims.

SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20090143323A1>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

We claim:

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Ebola genome in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding Ebola, and wherein said region of complementarity is less than 30 nucleotides in length.
2. The dsRNA of claim 1, wherein said first sequence is selected from the group consisting of the sense sequences of Table 2 and said second sequence is selected from the group consisting of the antisense sequences of Table 2.
3. The dsRNA of claim 1, wherein said dsRNA comprises at least one modified nucleotide.
4. The dsRNA of claim 2, wherein said dsRNA comprises at least one modified nucleotide.
5. The dsRNA of claims 3, wherein said modified nucleotide is chosen from the group of: a 2'-O-methyl modified

nucleotide, a nucleotide comprising a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholestry derivative or dodecanoic acid bisdecylamide group.

6. The dsRNA of claim 3, wherein said modified nucleotide is chosen from the group of: a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

7. The dsRNA of claims 3, wherein said first sequence is selected from the group consisting of the sense sequences of Table 2 and said second sequence is selected from the group consisting of the antisense sequences of Table 2.

8. The dsRNA of claim 6, wherein said first sequence is selected from the group consisting of the sense sequences of Table 2 and said second sequence is selected from the group consisting of the antisense sequences of Table 2.

9. A cell comprising the dsRNA of claim 1.

10. A pharmaceutical composition for inhibiting the expression of a gene from an Ebola virus in an organism, comprising a dsRNA of claim 1 and a pharmaceutically acceptable carrier.